6.3.5.4. comparison adjuvant- salvage radiotherapy. two retrospective matched studies (510 149 patients receiving art) failed show advantage mfs . however, studies underpowered high-risk patients (pt3b/r1/isup grade group 4–5 pca). contrast studies, propensity score-matched retrospective analysis two cohorts 366 pt3 and/or r1 patients found compared srt psa 0.1 0.5 ng/ml, art given undetectable psa (< 0.1 ng/ml) improved three endpoints; bcr, mfs, os . approaches (art early srt) together efficacy adjuvant adt compared three prospective rcts: medical research council (mrc) radiotherapy androgen deprivation combination local surgery (radicals) trial , trans-tasman oncology group (trog) radiotherapy adjuvant versus early salvage (raves) trial , groupe d’etude des tumeurs uro- genitales (getug-afu 17) trial . addition, pre-planned meta-analysis three trials published (table 6.3.5.2) . two trials closed early randomising 333/470 patients (raves) 424/718 (getug-afu-17) patients. radicals-rt included 1,396 patients option subsequent inclusion radicals-ht; 154/649 (24%) patients starting adjuvant rt group also received neoadjuvant adjuvant ht; 90 patients six months/45 2 years/19 patients outside radicals-ht. srt group, 61/228 (27%) received neoadjuvant adjuvant ht six months (n = 33) two years (n = 13). fifteen patients treated outside trial . men getug-afu-17 trial (n = 424) received six months ht. together, 684 2,153 patients received additional adt least six months across trials . radiotherapy pelvic lymphatics allowed getug-afu radicals-rt trials. primary endpoint raves getug-afu 17 biochemical pfs, radicals-rt mfs. far pfs data reported, mfs- os data. median follow-up 4.9 years 6.25 years statistically significant difference biochemical pfs treatments three trials (see table 6.2.5.2) indicating majority patients adjuvant irradiation avoided. additionally, significant lower rate grade ≥ 2 gu late side effects grade 3–4 urethral strictures favour early srt; may also caused low number patients psa-progression subsequent need early srt time analysis (40% patients). important note indication art changed last ten years introduction ultra-sensitive psa-tests, favouring early srt. therefore many patients, randomised three trials (accruing 2006–2008) likely benefit art low risk biochemical progression (~20–30%) in, example, pt3r0 pt2r1-tumours. median pre-srt psa 3 trials 0.24 ng/ml. therefore, patients ‘low-risk factors’ biochemical progression rp closely followed ultra-sensitive assays srt discussed needed soon psa starts rise, confirmed second psa measurement (see section 6.3). proportion patients adverse pathology rp (isup grade group 4–5 pt3 without positive margins) three trials low (between 10–20%) therefore even meta-analysis may underpowered show outcome favour srt . addition, side-effect profile may impacted larger proportion art patients receiving treatment older 3d-treatment planning techniques compared srt patients (getug-afu 17: art, 69% 3d vs. 46% srt) patients treated recently likely undergo imrt techniques proven lower rate late side effects . reasons, 10-year os mfs endpoints results awaited drawing final conclusions. due small number patients adverse pathology (isup grade group 4–5 pt3) included three trials (between 10–20%), art remains recommended treatment option highly selected patients adverse pathology (‘high-risk patients’) i.e. isup grade group 4–5 pt3 without positive margins . recommendation supported published retrospective multi-centre study comparing art srt patients high-risk features (pn1 isup grade group 4–5 pt3/4-tumours) rp . aftera median follow-up 8.2 years 26,118 men included study, 2,104 patients died, 25.62% pca (n = 539) 2,424 patients adverse pathology compared 23.694 not. excluding men persistent psa rp, art compared early srt showed significantly lower acute mortality risk(p = 0.02, hr: 0.33). table 6.3.5.2: overview three randomised trials one meta-analysis patients treated adjuvant vs. early salvage rt rp studyninclusion criteriarandomisationdefinition bcr psa(ng/ml)median fu (yr)bpfsos mfsside effectsravestrog 08.03/anzup2020 333targetwas 470earlyclosedpt3a/pt3bany - sm+psa post-rp:< 0.1 ng/ml64 gy art psa:< 0.1 ng/ml vs.64 gy early srtat psa> 0.2 ng/mlmed. pre-srt: n.r.> 0.4 post rt6.15 yr.:86% vs. 87%(p > 0.05)n.r.lt grade> gu:70% vs.54%(p = 0.002)radicals-rt2020 1,396pt3a/pt3b/pt4psa> 10 ng/mlpre-rpany t, sm+gleason7-10psa post-rp:< 0.2 ng/ml52.5 gy (20 fx)or 66 gy (33 fx) artearly srtidenticalat psa > 0.1med.pre-srt:0.2 ng/ml> 0.4 2 time4.95 yr.:85% vs. 88%(p = 0.56)n.r.self-reported urinary incontinence 1 yr: 4.8 vs.4 (p = 0.023)urethralstricturegrade 3/4 2 yr:6% vs. 4%(p = 0.02)getug-afu172020 424target was718early closedpt3a/pt3b/pt4a sm + psapost-rp:< 0.1 ng/ml66 gy (art) vs.66 gy early srtat psa 0.1both groups:6 mo. lhrh-amed. pre-srt 0.24> 0.46.255 yr:92% vs. 90%(p = 0.42)n.r.lt grade > 2 gu 27% vs. 7%(p < 0.001)ed: 28% vs. 8%(p < 0.001)artistic-meta-analysis2020 2,153see abovesee abovesee above4.55 yr.:89% vs. 88%p = 0.7n.r.n.r. art = adjuvant radiotherapy; bcr = biochemical recurrence; bpfs = biochemical progression-free survival; ed = erectile dysfunction; fu = follow-up; fx = fraction; gu = genito-urinary; lhrh = luteinising hormonereleasing hormone; lt = late toxicity; mo = months; med = median; mfs = metastasis-free survival; n.r. = reported; os = overall survival; psa = prostate-specific antigen; rp = radical prostatectomy; rt = radiotherapy; srt = salvage radiotherapy; + = positive; yr = year.